Durable efficacy and consistent safety profile at 52 weeks in FINCH 1 and 3 studies of filgotinib in rheumatoid arthritis

Longer term analysis of this oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis, demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of treatment. Regulatory filing in EU was submitted in Aug 2019.


Biospace Inc.